论文部分内容阅读
目的探讨无创正压通气(Non-invasive positive pressure ventilation,NPPV)治疗免疫抑制相关性肺病失败的相关因素。方法对28例重症免疫抑制相关性肺病患者的临床资料进行回顾性分析。结果经NPPV治疗成功率为64.3%,失败率为35.7%。患者PaO2、氧合指数、不耐受、气胸、APACHE评分差异有统计学意义(P<0.05)。结论 NPPV治疗免疫抑制患者并发呼吸衰竭效果肯定,病情严重程度、基础疾病会影响NPPV的疗效,而不耐受、气胸是导致NPPVV失败的常见原因。
Objective To investigate the related factors of failure of noninvasive positive pressure ventilation (NPPV) in the treatment of immunosuppressive-related pulmonary disease. Methods The clinical data of 28 patients with severe immunosuppression-related lung disease were retrospectively analyzed. Results The success rate of NPPV treatment was 64.3%, the failure rate was 35.7%. PaO2, oxygenation index, intolerance, pneumothorax and APACHE score were significantly different (P <0.05). Conclusion NPPV treatment of patients with immune suppression of respiratory failure is valid, the severity of the disease, the underlying disease will affect the efficacy of NPPV, and intolerance, pneumothorax is a common cause of NPPVV failure.